Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine for the treatment of francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.
Metrics to compare | APLI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAPLIPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.9x | −0.1x | −0.5x | |
PEG Ratio | −0.03 | 0.00 | 0.00 | |
Price/Book | −0.2x | 0.9x | 2.6x | |
Price / LTM Sales | 24.1x | 0.7x | 3.3x | |
Upside (Analyst Target) | - | 33.1% | 43.4% | |
Fair Value Upside | Unlock | 23.1% | 7.1% | Unlock |